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Permissive versus restrictive temperature
thresholds in critically ill children with fever
and infection: a multicentre randomized
clinical pilot trial
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Kentigern Thorburn12, Lyvonne Tume13, Jason Watkins6, Paul Wellman11, David A. Harrison4,
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Abstract
Background: Fever improves pathogen control at a significant metabolic cost. No randomized clinical trials (RCT)
have compared fever treatment thresholds in critically ill children. We performed a pilot RCT to determine whether
a definitive trial of a permissive approach to fever in comparison to current restrictive practice is feasible in critically
ill children with suspected infection.
Methods: An open, parallel-group pilot RCT with embedded mixed methods perspectives study in four UK
paediatric intensive care units (PICUs) and associated retrieval services.
Participants were emergency PICU admissions aged > 28 days to < 16 years receiving respiratory support and
supplemental oxygen.
Subjects were randomly assigned to permissive (antipyretic interventions only at ≥ 39.5 °C) or restrictive groups
(antipyretic interventions at ≥ 37.5 °C) whilst on respiratory support. Parents were invited to complete a questionnaire
or take part in an interview. Focus groups were conducted with staff at each unit. Outcomes were measures of
feasibility: recruitment rate, protocol adherence and acceptability, between group separation of temperature and safety.
Results: One hundred thirty-eight children met eligibility criteria of whom 100 (72%) were randomized (11.1 patients
per month per site) without prior consent (RWPC). Consent to continue in the trial was obtained in 87 cases (87%). The
mean maximum temperature (95% confidence interval) over the first 48 h was 38.4 °C (38.2–38.6) in the restrictive
group and 38.8 °C (38.6–39.1) in the permissive group, a mean difference of 0.5 °C (0.2–0.8). Protocol deviations were
observed in 6.8% (99/1438) of 6-h time periods and largely related to patient comfort in the recovery phase. Length of
stay, duration of organ support and mortality were similar between groups. No pre-specified serious adverse events
occurred. Staff (n = 48) and parents (n = 60) were supportive of the trial, including RWPC. Suggestions were made to
only include invasively ventilated children for the duration of intubation.
(Continued on next page)
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Conclusion: Uncertainty around the optimal fever threshold for antipyretic intervention is relevant to many emergency
PICU admissions. A more permissive approach was associated with a modest increase in mean maximum temperature.
A definitive trial should focus on the most seriously ill cases in whom antipyretics are rarely used for their analgesic
effects alone.
Trial registration: ISRCTN16022198. Registered on 14 August 2017.
Keywords: Sepsis, Infection, Paediatric intensive care, Fever, Paracetamol, Antipyretics, Clinical trial
Background
The fever response has been conserved across animal [1]
and even plant species [2] throughout evolution for at
least 580 million years [3]. Numerous innate and adap-
tive immunological processes are accelerated by fever [3,
4]. More rapid recoveries are observed from chickenpox
[5], malaria [6] and rhinovirus [7] infections with avoid-
ance of antipyretic medication. The UK National Insti-
tute for Health and Care Excellence (NICE) recommend
not using antipyretic agents “with the sole aim of redu-
cing body temperature in children with fever.” [8]. There
is uncertainty if these immunological advantages of fever
outweigh the associated increase in metabolic demand
(~ 10% increment in in oxygen consumption per degree
centigrade) during critical illness [9].
Observational data in critically ill adults suggest lower
mortality with higher peak temperatures in the first 24 h
in the context of infection [10]. Randomized clinical tri-
als (RCTs) of antipyretic interventions in critically ill
adults are mostly small (26–200 patients) and do not
show any consistent effect on early mortality [11–14]. In
a recent meta-analysis including eight randomized trials,
the relative risk for mortality in sepsis with fever control
compared with either no control or a more permissive
threshold was 0.93, (95% confidence interval 0.77 to 1.13)
[15]. The recent HEAT trial (ACTRN12612000513819)
examined the effect of acetaminophen versus placebo to
treat fever in 700 critically ill adults with known or sus-
pected infection [9]. Neither mortality nor the number of
ICU-free days to day 28 was significantly different. Chil-
dren differ from adults in both immunity and causes of in-
fection, and hence inferences from adult practice may not
be appropriate. We are not aware of any RCTs comparing
antipyretics or fever thresholds in critically ill children.
This pilot RCT was conducted to determine the safety
and feasibility of a definitive multicentre trial comparing
a restrictive approach to fever with a more permissive
threshold in critically ill children, with the following ob-
jectives: (1) to test the willingness of clinicians to screen,
recruit and randomize eligible patients, (2) to estimate
the recruitment rate, (3) to test acceptability of the trial,
consenting procedures and participant information, (4)
to test, following randomization, delivery of, and
adherence to the selected temperature thresholds (inter-
vention and control) for antipyretic intervention and to
demonstrate separation between the randomized groups
in temperature measurements, (5) to inform on the like-
lihood of major safety concerns, and (6) to inform final
selection of a patient-centred primary outcome measure.
The underlying hypothesis is that a more permissive
threshold for use of antipyretic interventions is superior
to the current restrictive approach.
Methods
Trial design and oversight
The FEVER pilot trial was a pragmatic, open,
parallel-group multicentre RCT in infants and children
accepted for emergency admission to one of four partici-
pating paediatric intensive care units (PICUs). The units
represented a geographical spread across England and a
variety of common configurations for UK PICUs (gen-
eral or combined general and cardiac units in general
academic medical centres or within stand-alone chil-
dren’s hospitals).
The trial was coordinated and sponsored by the Inten-
sive Care National Audit & Research Centre (ICNARC)
Clinical Trials Unit (CTU).
Health Research Authority and research ethics com-
mittee (17/LO/1139) approval was obtained. The proto-
col was registered (ISRCTN16022198) prior to
recruitment of the first patient. A trial steering commit-
tee, with a majority of independent members, and an in-
dependent data monitoring and ethics committee were
convened to oversee the trial on behalf of the funder.
The full trial protocol is available in the supplementary
appendix.
Trial population and eligibility criteria
Inclusion criteria were as follows: > 28 days and < 16
years of age, unplanned admission to a participating
PICU, fever ≥ 37.5 °C in the first 48 h following contact
with the paediatric retrieval service or PICU, new re-
quirement for mechanical ventilation and the treating
clinician presumed the cause of the fever was an infect-
ive process. Mechanical ventilation was considered to
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include invasive ventilation, non-invasive ventilation and
high-flow humidified oxygen.
Exclusion criteria were as follows: acute encephalop-
athy, including convulsive status epilepticus; post-cardio-
pulmonary bypass or known/suspected cardiomyopathy/
myocarditis; rhabdomyolysis (a serum creatine kinase
concentration at least 10 times the upper limit of nor-
mal); malignant hyperthermia, neuroleptic malignant
syndrome or drug-induced hyperthermia; receiving pal-
liative care or death perceived as imminent; and previ-
ous recruitment to the FEVER pilot trial. These
exclusions reflected populations that clinical staff were
not in equipoise about the risks and benefits of fever
control [16].
Screening and randomization
Potentially eligible infants and children were screened
against the eligibility criteria by the paediatric retrieval
team or PICU staff. Randomization took place as soon
as eligibility was confirmed, including during transport.
Participants were randomly allocated (1:1) via a secure
web-based system.
Trial interventions
Participants received antipyretic interventions at a
temperature threshold of either 37.5 °C in the restrictive
group or 39.5 °C in the permissive group, until they were
no longer receiving any mechanical ventilator support.
The 37.5 °C value was selected to represent usual care
following extensive feasibility work demonstrating that
approximately 60% of emergency PICU admissions re-
ceive antipyretic interventions at or below this
temperature. The site and technique for temperature
measurement and all other care were at the discretion of
the treating clinical teams.
Data collection
A secure, study-specific, web portal was developed
containing an electronic case report form. These data
were then combined with routinely collected UK
Paediatric Intensive Care Audit Network (PICANet;
www.picanet.org.uk) data.
Consent procedures
We employed a “research without prior consent”
(RWPC) approach as is appropriate in emergency situa-
tions where it is not practically possible to obtain con-
sent prospectively and any delay in commencing
treatment allocation may be detrimental [17]. A member
of the research team approached the parents/legal repre-
sentatives as soon as it was possible and appropriate
after randomization to discuss the trial, to provide a par-
ticipant information sheet (supplementary material) and
seek consent for continued inclusion in the trial. If the
participant was discharged or died prior to their par-
ents/legal representatives being approached, then they
were approached by an appropriate team member at a
later point either in person or by post with an option to
opt out from the trial [17].
Outcome measures and sample size calculation
The following outcome measures were used to assess
the specified objectives. Objective 1: the proportion of
eligible patients recruited (target 50%). Objective 2: the
number of eligible patients recruited per month (esti-
mated at 6.25 per site per month). Objective 3: staff and
parents’ views on the intervention thresholds and trial
procedures and the proportion of parents/legal represen-
tatives refusing or withdrawing consent. Objective 4: the
difference in maximum temperature between the re-
strictive and permissive groups in the first 48 h, propor-
tion of 6-h time periods in which antipyretic
interventions were used as directed in the trial protocol.
Objectives 5: occurrence of serious adverse events in
each group. Objective 6: characteristics and complete-
ness of potential primary endpoints for a definitive trial
including length of PICU stay, length of invasive ventila-
tion, ventilator-free days at day 30, duration of organ
support and PICU mortality.
As a pilot RCT, no formal sample size calculations
were performed, instead a sample size of 100 was deter-
mined to be adequate to estimate candidate
patient-centred outcome measures to a necessary degree
of precision and to test the trial processes. It was antici-
pated that this sample size would give 90% power to
demonstrate a separation of 0.5 °C in mean peak
temperature between temperature groups allowing for
16% withdrawal. 0.5 °C was chosen on the basis of the
HEAT trial [9] and our own observational work of the
impact of antipyretics on fever in PICU [18].
Statistical analysis
All analyses were carried out by the randomized group.
Continuous variables were summarized as mean (stand-
ard deviation) and median (interquartile range) whilst
categorical variables were summarized as number (per-
centage). Analyses were conducted using Stata/SE Ver-
sion 14.0 (StataCorp LP, College Station, US).
Parent and staff perspectives
To explore key stakeholder perspectives on trial accept-
ability, approach to consent and participant information,
we invited parents to complete a questionnaire following
the FEVER pilot trial recruitment discussion and/or par-
ticipate in an interview approximately a month after
leaving hospital. We also invited staff involved in the
pilot trial to take part in a focus group at the end of re-
cruitment. Interviews and focus groups were audio
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recorded after consent was obtained. Questionnaire and
topic guides were developed using previous research [19,
20] and pre-pilot trial qualitative study findings (re-
ported separately) that explored staff and parent per-
spective on trial design. Qualitative data analysis was
thematic and iterative [21]. Interviews continued until
no new themes were identified (data saturation) [22].
Quantitative data were analysed using simple descriptive
statistics. Data synthesis was pragmatic and drew on the
constant comparative approach [23].
Results
Objectives 1 and 2: Screening and recruitment rate
Between 25 September and 19 December, 2017, 154 pa-
tients were screened and met the inclusion criteria
(Fig. 1). Of these, 15 (9.7%) were excluded. Of those eli-
gible, 26 (18.7%) were missed and 12 (8.6%) were not
randomized due to local clinical decisions. One hundred
one (72.7%) children were randomized into the pilot
trial. One patient was removed as a duplicate. 72.5%
(100/138) of eligible patients were appropriately ran-
domized. The recruitment rate of 11.1 (95% confidence
interval 9.0–13.5) patients per site per month was al-
most double that estimated from PICANet data.
Objective 3: Trial acceptability, including consent process
and patient information
Of the 100 patients, five (four in the permissive group)
were unable to be approached for consent. These in-
cluded children in the care of social workers and parents
who were felt to have insufficient understanding of trial
information. Consent to continue in the trial was refused
in eight out of the remaining 95 patients. Of these, seven
had been allocated to the permissive treatment group. In
addition, parents/legal representatives of seven patients
(five permissive and two restrictive) refused consent to
be treated according to the trial protocol, but consented
for ongoing data collection, and a further three patients
treated in the permissive group withdrew consent so as
to allow an antipyretic intervention to be given. One
hospital had seven out of their 10 patients randomized
to the permissive group have consent either refused or
withdrawn, which accounted for almost half (46.7%) of
the total number across all four sites.
Therefore, 87 out of the 100 correctly randomized pa-
tients were included in the analysis of objectives 4–6.
A total of 60 parents (49 mothers, 11 fathers) of 57/
100 (57%) randomized children took part in a question-
naire (41/60, 68%), an interview (12/60, 20%) or both (7/
60, 12%). Eight (six questionnaire and two interview par-
ticipants) had refused consent for their child’s involve-
ment in the FEVER pilot trial. Forty-eight staff (9/48,
19% medical; 39/48, 81% nursing) participated in one of
five focus groups held at the four participating PICUs.
All parents interviewed described their support for the
trial (see Table 1), which was viewed “an interesting trial”
(P30, interview, mother, restrictive), involving a per-
ceived low risk, non-invasive intervention, of which par-
ents were familiar. Many of the questionnaire
respondents (32/42, 76%) cited helping other children in
the future as their main reason for providing consent,
whilst during interviews parents emphasized how they
trusted doctors to prioritize their child’s well-being
whilst they were in the FEVER pilot trial. Reasons the
eight parents provided for declining consent included
concerns about their child being in pain or discomfort,
increased physiological workload, pre-existing medical
condition, risk of epileptic seizures due to family history
and incapacity to make an informed decision (see
Table 1). Two parents withdrew consent due to concerns
about their child being in pain or discomfort during
deintensification. Importantly, parents who declined
consent to use data already collected, or for their child
to continue in the FEVER pilot trial, also described their
support for the proposed definitive RCT.
The majority (42/48, 89% of questionnaire respon-
dents) indicated they were satisfied with the FEVER con-
sent process. Four (4/48, 9%) indicated that they were
not satisfied with the use of RWPC, although this had
not influenced their decision to agree or decline consent.
Those who took part in an interview also described how
the consent discussion had been well timed and how
staff had “clearly explained” (P74, interview, mother, per-
missive) the trial. Participant information materials were
viewed as being “clear and understandable” (P80, inter-
view, mother, permissive).
Baseline patient characteristics
Overall, the two treatment groups were well matched at
baseline (Table 2). Bronchiolitis was the most common
diagnosis. Baseline temperature was the same in both
groups; however, a greater proportion of patients in the
restrictive temperature arm received pre-randomization
paracetamol (Additional file 1: Table S3).
Objective 4: Protocol adherence and separation between
the groups
Over the first 48 h following randomization, patients in
the restrictive group had a mean peak temperature of
38.4 °C (95% confidence interval 38.2–38.6 °C) compared
with 38.8 °C (38.6–39.1 °C) in the permissive group. This
resulted in a between-group difference in mean peak
temperature over the first 48 h of 0.5 °C (0.2–0.8 °C).
The separation of around 0.5 °C was maintained up to
84 h following randomization (Fig. 2). More patients re-
ceived antipyretic interventions in the restrictive group
(98%, 48/49) than in the permissive group (50%, 19/38)
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in the 48 h following randomization (Additional file 1:
Table S6).
Protocol deviations were assessed for each patient
during each 6-h time period from randomization until
death or discharge from PICU. Either not receiving
an antipyretic intervention when above the allocated
threshold or receiving such an intervention without
reaching the threshold were considered deviations.
(These definitions are likely to represent
overestimates of non-adherence because of interven-
tions in previous, or immediately following, time pe-
riods not being considered). Deviations were reported
in 39 of 628 6-h time periods (6.2%) in the permissive
group and 60 out of 810 time periods (7.4%) in the
restrictive group. Overall, 39% of patients in the per-
missive group and 55% in the restrictive group expe-
rienced at least one 6-h period containing a protocol
deviation (Table 2).
Fig. 1 Flow of participants through the pilot randomized clinical trial
Peters et al. Critical Care           (2019) 23:69 Page 5 of 11
The embedded qualitative work investigated staff at-
titudes that may have contributed to non-adherence.
Staff had mixed views about the acceptability of the
permissive temperature threshold. Focus group partic-
ipants who did not find the permissive threshold ac-
ceptable described how they were unhappy about not
administering paracetamol when they thought a child
was uncomfortable or in pain. This led to protocol
deviations. Suggestions were made to revise the pro-
posed FEVER pilot trial protocol to exclude patients
not on mechanical ventilation (e.g. high-flow nasal
oxygen) or those close to being extubated when sed-
ation is being weaned.
Overall, the majority of staff described their support
for a definitive trial, often stating this trial was needed to
provide an answer to an important research question.
Table 1 Staff and parent perspectives from interviews, focus groups and questionnaires by theme
Theme Subtheme Illustrative quotations
Trial acceptability Parent support influenced by the nature
of the intervention
“‘I think it’s a brilliant idea, so I am all, I am all for it” (Parent 80, interview mother,
permissive).
“It’s just how are they gonna give the Paracetamol, when they are gonna give it.
I mean if it was more severe, um, more of an invasive study, um, I might have been
a bit, I might have had to query it a little bit more but I was happy with, with
everything” (Parent 53, interview, father, restrictive).
Main reasons for consent—trust in
doctors/wanting to help others
“If we can find the information to help other children in the future; that would
be good” (Parent 35, interview, mother, restrictive).
“She’s in a hospital. I mean them people know better than me, so I understand
that they would never put a child in harm’s way” (Parent 81, interview, father,
restrictive).
Reasons for declining consent Concerns about their child being in pain or discomfort (3 parents)
“We just felt because he could not tell us how he was feeling, like whether
he was okay, or whether he was in pain, it was very difficult” (Parent 84,
interview, mother, permissive)
Concern about increased workload (1 parent)
“I think allowing her paracetamol to help her temp and heart rate benefits her
not tiring” (Parent 68, questionnaire, mother).
Concerns about negative impact due to child’s pre-existing medical conditions (3 parents)
“I think it was, if he had no other underlying medical condition then, and
maybe if we had not have been in hospital for 16 weeks previous to that,
then possibly, yeah” (Parent 84, interview, mother, permissive).
Risk of seizures due to family history (1 parent)
“My nephew has seizures [..] So we just decided that we just did not want
that to even be a possibility” (Parent 84, interview, mother, permissive).
Incapacity and research evidence needed (1 parent)
“At the time he had too much other stuff going on for us to even think
about being involved in the study[…] it’s seeing whether there is any
research and proof that giving paracetamol straight away is the right thing
to do or whether it would go away by itself” (Parent 83, interview, mother,
permissive).
Deintensification as a reason for
withdrawing consent
“The only time we eventually pulled him from the trial and gave him paracetamol
was when he was awake and he was a lot more distressed, and that was harder
for me to watch, especially, especially the way he was, and I said, look, if it’s
gonna help, I’d rather you gave him it, but when he was sedated and he was
ventilated and everything, he did get a temperature and, like I say, he brought
it back down himself” (Parent 49, interview, mother, permissive).
“He was withdrawn because, um, he did not actually have a temperature at
all and he was in a little bit of pain once he’d been extubated. So they wanted
to give him some Paracetamol but he did not have any temperature any way”
(Parent 76, interview, mother, permissive).
Staff concerns and protocol adherence “I thought it [permissive threshold] was too high because at that stage the
patient I was looking after was, was very distressed and very uncomfortable
from what I remember I gave paracetamol because I did not fi-, I did not think
it was fair on the child to leave them that hot and that distressed” (Staff 01,
focus group 3).
“we are much happy to, happier to be compliant, erm, if the child was
intubated and ventilated and knocked out” (Staff 05, focus group 2).
Research without
prior consent
Acceptable in the proposed trial “I do not think there’s any other way better to go about it” (P79,
interview, mother, restrictive).
“So many of the trials that we have done over the last few years have
worked in the same way, without getting consent and things, it’s actually
more normal than, hold on a minute, I cannot do that, we need to get
consent first” (Staff 01, focus group 5).
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“You’re never gonna know the answer if you don’t do
a trial” (Staff 04, focus group 2).
Objective 5: Safety
There were no reported serious adverse events.
Three adverse events in total were reported. One
seizure was reported in the permissive group (an
expected adverse event) that was deemed unlikely
to be related to the trial intervention. There were
two adverse events in the restrictive group: one
seizure that was deemed unrelated and one rhabdomyoly-
sis (an expected adverse event) (Additional file 1:
Table S4).
Table 2 Baseline patient characteristics by treatment group
Variables Permissive Restrictive Total
N = 38 N = 49 N = 87
Age (years)
Mean (SD) 1.8 (3.4) 1.1 (2.1) 1.4 (2.7)
Age group (years), n (%)
< 1 24 (63.2) 32 (65.3) 56 (64.4)
1 3 (7.9) 4 (8.2) 7 (8.0)
2–4 5 (13.2) 9 (18.4) 14 (16.1)
5–9 3 (7.9) 3 (6.1) 6 (6.9)
10–15 3 (7.9) 1 (2.0) 4 (4.6)
Gender, n (%)
Female 14 (36.8) 22 (44.9) 36 (41.4)
PIM2r scorea
Mean (SD) 0.025 (0.030) 0.025 (0.030) 0.025 (0.029)
Median (IQR) 0.012 (0.008,0.035) 0.012 (0.008,0.037) 0.012 (0.008,0.036)
PIM3 score
Mean (SD) 0.023 (0.033) 0.025 (0.036) 0.024 (0.034)
Median (IQR) 0.007 (0.005,0.033) 0.007 (0.005,0.038) 0.007 (0.005,0.037)
Source of admission, n (%)
Same hospital 6 (15.8) 13 (26.5) 19 (21.8)
Other hospital 32 (84.2) 36 (73.5) 68 (78.2)
Primary diagnosis, n (%)
Bronchiolitis 19 (50.0) 24 (49.0) 43 (49.4)
Pneumonia/LRTI 9 (23.7) 8 (16.3) 17 (19.5)
Acute respiratory failure 4 (10.5) 7 (14.3) 11 (12.6)
Sepsis/septic shock 2 (5.3) 6 (12.2) 8 (9.2)
Asthma 2 (5.3) 1 (2.0) 3 (3.4)
Seizures/convulsions 1 (2.6) 2 (4.1) 3 (3.4)
Other 1 (2.6) 1 (2.0) 2 (2.3)
Temperature prior to randomization (°C)
Mean (SD) 38.1 (0.6) 38.1 (0.7) 38.1 (0.6)
Median (IQR) 38.0 (37.7,38.6) 37.9 (37.6,38.3) 37.9 (37.7,38.5)
Type of ventilation, n (%)
High-flow humidified O2, n (%) 0 (0) 2 (4.1) 2 (2.3)
Non-invasive, n (%) 3 (7.9) 3 (6.1) 6 (6.9)
Invasive n (%) 35 (92.1) 44 (89.8) 79 (90.8)
N total number of patients, n number of patients, SD standard deviation, IQR interquartile range
a2016 recalibration
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Objective 6: Potential primary outcome for a definitive
trial
For the 86 patients consenting to data collection and
having left hospital at the time of data lock, all candidate
outcome data were complete on consented patients.
Characteristics of the outcome measures are outlined in
Table 3, as expected for a pilot trial of this size, there
were no significant differences between the groups in
any of the outcomes.
Discussion
In this multicentre, pilot RCT with embedded perspec-
tives study, we investigated the feasibility of conducting
a large-scale trial comparing a permissive threshold of
antipyretic intervention (≥ 39.5 °C) with a restrictive
threshold (≥ 37.5 °C) in critically ill children receiving re-
spiratory support.
We observed that the eligibility criteria were effective
in identifying patients and that clinicians were prepared
to randomize these patients without seeking prospective
informed consent. Our initial estimates of the number of
emergency admissions from registry data who met these
criteria were shown to be conservative. The rate of re-
cruitment of eligible patients was high with recruitment
being completed in approximately half the anticipated
time. Parents were overwhelmingly supportive of the
RWPC process which is in line with recent findings in
the recent Fluids in Shock [20], FIRST-ABC [24] and
Oxy-PICU [25] studies.
Nevertheless, there was concern about the acceptabil-
ity of the permissive protocol to parents and bedside
nursing staff. This was manifest in both the number of
protocol deviations—albeit against a very strict definition
of adherence—and, more importantly, in a high number
of instances of consent being declined or withdrawn in
the permissive group. Our embedded study revealed that
the driver of staff non-adherence and some parents
withdrawing consent was concern about patient discom-
fort or pain, particularly during deintensification with re-
ductions in analgesic and sedative infusions. Staff
A
B
Fig. 2 Distribution of peak temperatures in each 6-h period from randomization by treatment group. a Median, interquartile ranges and range for
each group and b between-group differences in means of maximum each 6-h period
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suggested that only including invasively ventilated chil-
dren for the duration of intubation would help to
minimize these issues.
The variability in consent rates by institution as well
as parent and staff views on approaches to consent and
trial acceptability will inform our site training for ap-
proaching families in a definitive trial.
The protocol achieved a highly significant separation
of the groups in terms of observed maximum
temperature values especially in the first few days of
PICU admission. It is noteworthy that our observed dif-
ference in temperature was similar to that achieved in
the very much larger HEAT trial of paracetamol or pla-
cebo in critically ill adults [9].
Our pilot trial shares weaknesses shared with many tri-
als in critically ill children. Exclusion of cases with acute
encephalopathy or congenital cardiac disease limits the
generalizability of any findings to a subset of critically ill
children. These were felt to be necessary because of our
work scoping current practice and equipoise. We did not
attempt to control antipyretic therapy prior to PICU refer-
ral. We did not attempt to blind clinical staff to the group
allocation. Our pragmatic approach meant that clinicians
were free to adopt different hemodynamic goals, oxygen-
ation targets or transfusion thresholds that might alter the
balance between oxygen delivery and consumption inde-
pendent of the body temperature thresholds. In addition,
as a feasibility trial, we cannot make any conclusions on
the effectiveness of a permissive approach to fever.
There are several strengths of FEVER beyond it being
the first report of a randomized comparison of permis-
sive and restrictive temperature thresholds in critically ill
children. We have demonstrated a high degree of en-
gagement of clinical staff with the protocol across differ-
ent units and transport teams. The trial processes were
largely acceptable to parents and parents. No safety is-
sues were identified and clinical outcomes were readily
collected and suitable for a definitive trial.
Table 3 Potential outcome measures by treatment group
Potential outcome measures Permissive (N = 38) Restrictive (N = 49) Effect estimate (95% CI)
PICU mortality, n/N (%) 1/37 (2.7) 1/49 (2.0) 1.3 (0.1, 20.5)a − 0.7 (− 7.2, 5.9)b
Hospital mortality, n/N (%) 1/36 (2.8) 2/46 (4.3) 0.6 (0.1, 6.8)a 1.6 (− 6.4, 9.5)b
30-day mortality, n/N (%) 2/37 (5.4) 1/49 (2.0) 2.6 (0.2, 28.1)a − 3.4 (− 11.7, 4.9)b
Length of stay in PICU (days)
All patients N = 37 N = 49
Mean (SD) 7.3 (4.3) 8.1 (8.6)
Median (IQR) 6 (4, 10) 6 (4, 8)
Survivors to PICU discharge N = 36 N = 48
Mean (SD) 7.2 (4.3) 7.9 (8.5)
Median (IQR) 6 (4, 9) 6 (4, 8)
Receipt and duration of organ supportc
Mechanical ventilation, n (%) 38 (100) 49 (100)
Median (IQR) 5 (3, 8) 5 (3, 7)
Mean (SD) 6.5 (4.6) 6.2 (5.5) 0.3 (− 1.8, 2.5)d
Cardiovascular support, n (%) 8 (21.1) 13 (26.5)
Median (IQR) 2 (2, 3) 3 (2, 6)
Mean (SD) 0.5 (1.1) 1.2 (2.9) − 0.7 (− 1.6, 0.2)d
Renal support, n (%) 1 (2.6) 3 (6.1)
Mean (SD) 0.4 (2.4) 0.3 (1.6) 0.1 (− 0.8, 1.0)d
Median (IQR) N < 5 N < 5
Days alive and free (to 28 days) from
PICU, mean (SD) [N] 19.8 (6.4) [37] 20.4 (6.2) [49] − 0.7 (− 3.4, 2.1)d
Mechanical ventilation, mean (SD) 20.5 (6.7) [38] 21.6 (6.1) [49] − 1.1 (− 3.8, 1.7)d
SD standard deviation, IQR interquartile range, CI confidence interval
aRisk ratio
bAbsolute risk reduction
cMean and standard deviation reported for all patients, median and interquartile range reported for patients receiving the organ support only (where at least five
patients in each group received the support)
dMean difference
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Although the choice of primary outcome measure for
a definitive trial will involve consultation with patients
and families and considerations of cost, timings and
competing studies, our data permit sample size estima-
tions. For example, a composite outcome of mortality
and duration of ventilation with 90% power to detect a
12-h difference in ventilation and no effect on mortality
would require a total of around 2000 patients. These
pilot data have identified the challenges involved in
attempting a definitive trial of fever management in crit-
ically ill children. Protocol amendments are likely to im-
prove adherence and retention in a definitive trial but an
internal pilot study would be prudent to confirm the im-
pact of these changes.
Conclusion
The FEVER pilot trial has demonstrated the feasibility of
conducting a definitive pragmatic clinical trial of
temperature thresholds for antipyretic interventions in
critically ill children with some reservations. These are
particularly around protocol adherence during recovery.
Limiting the intervention to the duration of invasive
ventilation may be appropriate.
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